LL-37 vs Pegzilarginase-nbln

Overview

LL-37 is primarily a immune support peptide, while Pegzilarginase-nbln is used for weight management & metabolic.

This page compares LL-37 and Pegzilarginase-nbln across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.

Side-by-side comparison

Key differences

Primary use. LL-37 is categorised under Immune Support, while Pegzilarginase-nbln falls under Weight Management & Metabolic. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.

Regulatory status. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026. Pegzilarginase-nbln: FDA-approved.

Dosing. LL-37 is typically dosed at 2-5 mg (twice weekly). Typical dosing for Pegzilarginase-nbln is not catalogued.

Can you stack them?

Some protocols combine peptides, but stacking LL-37 and Pegzilarginase-nbln has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.

Frequently asked questions

What is the difference between LL-37 and Pegzilarginase-nbln?

LL-37 is primarily a immune support peptide, while Pegzilarginase-nbln is used for weight management & metabolic. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026), whereas Pegzilarginase-nbln is FDA-approved for one or more indications.

What is LL-37 used for?

Antimicrobial defense peptide.

What is Pegzilarginase-nbln used for?

PEGylated recombinant arginase enzyme for Arginase 1 Deficiency. FDA approved February 23, 2026.

Can you take LL-37 and Pegzilarginase-nbln together?

Some users combine peptides within a single protocol, but stacking LL-37 and Pegzilarginase-nbln has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.

Is LL-37 or Pegzilarginase-nbln FDA-approved?

LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026). Pegzilarginase-nbln is FDA-approved for one or more indications.